Value investing, at its core, is the practice of buying a company for less than its intrinsic worth. The challenge lies in finding stocks that are genuinely undervalued without being value traps. The “Decent Value” screen is a method designed to do exactly that: it prioritizes stocks that offer strong valuation scores but also requires them to possess decent profitability, financial health, and growth. This balances the hunt for a bargain with the need for a fundamentally sound business, reducing the risk that the low price is simply a reflection of a decaying company. One stock that recently appeared on this screen is Envista Holdings Corp (NYSE:NVST).
Envista is a global dental products company that owns a large portfolio of trusted brands such as Nobel Biocare, Ormco, DEXIS, and Kerr. With over 30 brands spanning everything from implant systems to digital imaging, the company sits at the intersection of consumables and specialty technology within the dental industry.
Valuation: The Strongest Pillar
The most convincing reason for Envista as a value stock comes from its valuation scores. According to its fundamental analysis, Envista earns a Valuation rating of 7 out of 10. This score is built on a few key comparisons that show the stock is trading at a relative discount.
- Cheap vs. the Industry: Trading at a Price/Earnings ratio of 20.45, Envista is cheaper than 81.38% of its peers in the Health Care Equipment & Supplies industry. Even more striking is the Enterprise Value to EBITDA ratio, where the company is cheaper than 88.83% of its competitors.
- Cheap vs. the Broad Market: The current P/E ratio of 20.45 is also lower than the S&P 500’s average of roughly 26.78, indicating the stock is cheaper than the typical large-cap stock.
- Forward Looking Discount: The forward P/E ratio drops to 16.87, which is not only cheaper than 80.32% of the industry but also below the S&P 500’s forward average of 21.50.
For value investors, this suggests the market is currently pricing Envista below the pace of its industry and the general market, providing a potential margin of safety.
Growth: A Reason for Optimism
A cheap stock that isn't growing is often a value trap. Envista, however, shows a promising growth trajectory that helps justify its low valuation. It has a solid Growth rating of 6 out of 10.
The most impressive metric here is the explosive year-over-year earnings growth. EPS grew by a massive 85.92% over the past year, which is a strong turnaround signal. Revenue growth is also steady at 12.15% over the last year, with a consistent history growing at 7.11% annually.
Perhaps most important for the future is the accelerating trajectory. Analysts expect EPS to grow by 22.46% annually in the coming years, while revenue is projected to grow at 7.58%. This combination of strong forward growth and a low PEG ratio is a classic sign for value investors that the stock is not yet pricing in its future potential.
Profitability and Health: The Supporting Cast
The Decent Value screen requires profitability and health to be decent, and Envista fits that requirement.
Profitability (Score: 6/10): The company is profitable and cash-flow positive. Its margins are solid, with a Profit Margin that outperforms 73.94% of the industry and an Operating Margin that has been growing nicely. The Return on Invested Capital (ROIC) is currently 4.38%, which is trending upward and now above its 3-year average of 3.73%, signaling improving efficiency.
Financial Health (Score: 5/10): The health metrics show a mixed but manageable picture. The Altman-Z score of 1.86 places the company in a “grey zone,” but this is in line with its industry peers. More importantly, liquidity is strong; the current ratio of 2.44 and quick ratio of 2.06 both indicate the company can easily meet its short-term obligations. The Debt-to-Equity ratio of 0.47 is also healthy, suggesting a balanced use of debt versus equity.
While it is worth noting that the company is currently destroying value based on the WACC vs. ROIC comparison, the improving trajectory and strong liquidity provide a buffer against that risk.
Why This Matters for the Value Strategy
The Decent Value screen works because it prevents an investor from buying a “cheap” company that is bleeding cash or falling behind. Envista checks all the necessary boxes: it brings a compelling valuation, offers strong growth prospects, and exhibits decent profitability and liquidity. For investors interested in screening for similar opportunities, you can find more stocks that fit this profile by checking out the Decent Value Screen list. A deep look into the data that supports this analysis can be found on the fundamental analysis report.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Past performance and fundamental ratings are not guarantees of future results. Always conduct your own research before making an investment decision.
Read full article here »
View the Zacks #1 Rank List
Envista Holdings Corp (NYSE:NVST) Is a Decent Value Stock with Strong Growth Prospects
Value investing, at its core, is the practice of buying a company for less than its intrinsic worth. The challenge lies in finding stocks that are genuinely undervalued without being value traps. The “Decent Value” screen is a method designed to do exactly that: it prioritizes stocks that offer strong valuation scores but also requires them to possess decent profitability, financial health, and growth. This balances the hunt for a bargain with the need for a fundamentally sound business, reducing the risk that the low price is simply a reflection of a decaying company. One stock that recently appeared on this screen is Envista Holdings Corp (NYSE:NVST).
Envista is a global dental products company that owns a large portfolio of trusted brands such as Nobel Biocare, Ormco, DEXIS, and Kerr. With over 30 brands spanning everything from implant systems to digital imaging, the company sits at the intersection of consumables and specialty technology within the dental industry.
Valuation: The Strongest Pillar
The most convincing reason for Envista as a value stock comes from its valuation scores. According to its fundamental analysis, Envista earns a Valuation rating of 7 out of 10. This score is built on a few key comparisons that show the stock is trading at a relative discount.
For value investors, this suggests the market is currently pricing Envista below the pace of its industry and the general market, providing a potential margin of safety.
Growth: A Reason for Optimism
A cheap stock that isn't growing is often a value trap. Envista, however, shows a promising growth trajectory that helps justify its low valuation. It has a solid Growth rating of 6 out of 10.
The most impressive metric here is the explosive year-over-year earnings growth. EPS grew by a massive 85.92% over the past year, which is a strong turnaround signal. Revenue growth is also steady at 12.15% over the last year, with a consistent history growing at 7.11% annually.
Perhaps most important for the future is the accelerating trajectory. Analysts expect EPS to grow by 22.46% annually in the coming years, while revenue is projected to grow at 7.58%. This combination of strong forward growth and a low PEG ratio is a classic sign for value investors that the stock is not yet pricing in its future potential.
Profitability and Health: The Supporting Cast
The Decent Value screen requires profitability and health to be decent, and Envista fits that requirement.
Profitability (Score: 6/10): The company is profitable and cash-flow positive. Its margins are solid, with a Profit Margin that outperforms 73.94% of the industry and an Operating Margin that has been growing nicely. The Return on Invested Capital (ROIC) is currently 4.38%, which is trending upward and now above its 3-year average of 3.73%, signaling improving efficiency.
Financial Health (Score: 5/10): The health metrics show a mixed but manageable picture. The Altman-Z score of 1.86 places the company in a “grey zone,” but this is in line with its industry peers. More importantly, liquidity is strong; the current ratio of 2.44 and quick ratio of 2.06 both indicate the company can easily meet its short-term obligations. The Debt-to-Equity ratio of 0.47 is also healthy, suggesting a balanced use of debt versus equity.
While it is worth noting that the company is currently destroying value based on the WACC vs. ROIC comparison, the improving trajectory and strong liquidity provide a buffer against that risk.
Why This Matters for the Value Strategy
The Decent Value screen works because it prevents an investor from buying a “cheap” company that is bleeding cash or falling behind. Envista checks all the necessary boxes: it brings a compelling valuation, offers strong growth prospects, and exhibits decent profitability and liquidity. For investors interested in screening for similar opportunities, you can find more stocks that fit this profile by checking out the Decent Value Screen list. A deep look into the data that supports this analysis can be found on the fundamental analysis report.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Past performance and fundamental ratings are not guarantees of future results. Always conduct your own research before making an investment decision.
Read full article here »